BACKGROUND:Ferric citrate (FC) is a new phosphorus binder shown to increase serum iron stores while reducing intravenous iron and erythropoiesis-stimulating agent usage. Such reductions could lower hospitalization rates and associated costs. METHODS: Hospitalizations during a Phase III trial were compared between FC and active control (AC). Hospitalization costs were estimated using the 2013 US Renal Data System Annual Data Report. RESULTS: 34.6% of FC patients were hospitalized at least once versus 45.6% of the AC group (risk reduction 24.2%; p = 0.02). There were 181 unique hospitalizations in the FC group versus 239 in the AC group, for a difference of 58 hospitalizations. Total potential savings was US$ 867,622 in hospitalization costs in the FC group. If the hospitalization reduction in our study was applied to the general end-stage renal disease population, this could translate into a savings of US$ 3002/patient/year. CONCLUSIONS: Patients receiving FC experienced fewer hospitalizations with the potential for significant savings.
RCT Entities:
BACKGROUND:Ferric citrate (FC) is a new phosphorus binder shown to increase serum iron stores while reducing intravenous iron and erythropoiesis-stimulating agent usage. Such reductions could lower hospitalization rates and associated costs. METHODS: Hospitalizations during a Phase III trial were compared between FC and active control (AC). Hospitalization costs were estimated using the 2013 US Renal Data System Annual Data Report. RESULTS: 34.6% of FCpatients were hospitalized at least once versus 45.6% of the AC group (risk reduction 24.2%; p = 0.02). There were 181 unique hospitalizations in the FC group versus 239 in the AC group, for a difference of 58 hospitalizations. Total potential savings was US$ 867,622 in hospitalization costs in the FC group. If the hospitalization reduction in our study was applied to the general end-stage renal disease population, this could translate into a savings of US$ 3002/patient/year. CONCLUSIONS:Patients receiving FC experienced fewer hospitalizations with the potential for significant savings.
Authors: Peter N Van Buren; Julia B Lewis; Jamie P Dwyer; Tom Greene; John Middleton; Mohammed Sika; Kausik Umanath; Josephine D Abraham; Shahabul S Arfeen; Isai G Bowline; Gil Chernin; Stephen Z Fadem; Simin Goral; Mark Koury; Marvin V Sinsakul; Daniel E Weiner Journal: Am J Kidney Dis Date: 2015-05-07 Impact factor: 8.860
Authors: Roger A Rodby; Kausik Umanath; Robert Niecestro; T Christopher Bond; Mohammed Sika; Julia Lewis; Jamie P Dwyer Journal: Drugs R D Date: 2015-09
Authors: Daniel W Coyne; Linda H Ficociello; Vidhya Parameswaran; Melissa M Rosen; Claudy Mullon; Robert J Kossmann; Stuart M Sprague Journal: Kidney Med Date: 2020-03-26